American Headache Society recommend CGRP therapies for “first-line” migraine treatment
This is big news for migraine treatment, and a good indicator of how reliable and safe these new treatments are, compared to the previous generation: “All migraine preventive therapies previously considered to be first-line treatments were developed for other indications and adopted later for migraine. Adherence to these therapies is often poor due to issues with efficacy and tolerability. Multiple new migraine-specific therapies have been developed based on a broad foundation of pre-clinical and clinical evidence showing that CGRP plays a key role in the pathogenesis of migraine. These CGRP-targeting therapies have had a transformational impact on the management of migraine but are still not widely considered to be first-line approaches.” [….] “The CGRP-targeting therapies should be considered as a first-line approach for migraine prevention […] without a requirement for prior failure of other classes of migraine preventive treatment.” I hope to see this elsewhere soon, too — and I’m also hoping to be prescribed my first CGRP treatments soon so I can reap the benefits myself; migraines have been no fun.